佐力药业(300181) - 2024年5月10日投资者关系活动记录表

Group 1: Sales Performance - The sales volume and revenue of Wuling Capsule in Q1 2024 increased by 43.86% and 37.25% respectively compared to the same period last year, attributed to the execution of centralized procurement and the introduction of larger packaging in hospitals [2][3] - The company anticipates continued growth in the Beijing-Tianjin-Hebei "3+N" alliance as it expands into more provinces [2][3] Group 2: Mergers and Acquisitions - The company is actively seeking good acquisition opportunities, focusing on targets that have synergistic effects with existing products, particularly in neurology, psychiatry, and traditional Chinese medicine [3][4] - The company aims to leverage the current market conditions to identify quality acquisition targets that align with its development strategy [3][4] Group 3: OTC Sales and Marketing Strategy - OTC sales currently account for approximately 10% of the company's total sales, with an OTC team of about 100 members [3][4] - Future plans include enhancing C-end marketing, improving pharmacy coverage, and strengthening patient education to boost sales through e-commerce partnerships [3][4] Group 4: Product Development and R&D - The company will continue to focus on R&D in 2024, aiming for a balanced pipeline of projects at various stages of development [4] - Plans include developing a series of Wuling products, targeting a total of 10 varieties, and focusing on innovative drugs for Alzheimer's disease [4] Group 5: Revenue Distribution and Trends - Zhejiang province accounts for the highest sales revenue due to the company's local presence and the economic advantages of the region [4] - Other significant regions include Guangdong, Beijing, Shanghai, and Henan, with sales expected to increase as centralized procurement expands [4] Group 6: Sales Expense Trends - Sales expense ratios are expected to fluctuate with sales scale and new product launches, with a potential decrease in centralized procurement areas [4] - Increased marketing investments are anticipated with the launch of new products and efforts to enhance brand influence in the C-end market [4]